Quoin Pharmaceuticals, Ltd. (QNRX)
| Market Cap | 14.00M +214.8% |
| Revenue (ttm) | n/a |
| Net Income | -18.67M |
| EPS | -8.52 |
| Shares Out | 2.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,740 |
| Open | 7.09 |
| Previous Close | 7.15 |
| Day's Range | 6.84 - 7.10 |
| 52-Week Range | 3.25 - 41.80 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 22.20 (+218.51%) |
| Earnings Date | Aug 14, 2026 |
About QNRX
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for QNRX stock is "Strong Buy." The 12-month stock price target is $22.2, which is an increase of 218.51% from the latest price.
News
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Sk...
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003
Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome.
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Sk...
Quoin Pharmaceuticals announces $50M private placement
Quoin Pharmaceuticals (QNRX) announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50M in gr...
Quoin Pharmaceuticals reports ‘positive’ data from Phase 2/3 study of QRX003
Quoin Pharmaceuticals (QNRX) announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome. The primary endpoint of 1-grade...
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participant...
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)
“The second quarter was a highly productive period across both of our delivery technology platforms,” said Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals (QNRX). “Our I...
Quoin Pharmaceuticals Earnings release: Q2 2026
Quoin Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Quarterly report: Q2 2026
Quoin Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
Quoin Pharmaceuticals Earnings release: Q2 2026
Quoin Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Nethe...
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals Proxy statement: Proxy filing
Quoin Pharmaceuticals filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
Quoin Pharmaceuticals (QNRX) announced that the FDA has cleared the company’s investigational new drug, or IND, application for QRX003 for the treatment of Peeling Skin Syndrome, enabling initiation o...
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026
Quoin Pharmaceuticals Proxy statement: Proxy filing
Quoin Pharmaceuticals filed a proxy statement on July 6, 2026, providing details for shareholder voting and corporate governance matters.
Quoin Pharmaceuticals receives notice of allowance for QRX003 patent
Quoin Pharmaceuticals (QNRX) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice of allowance for U.S. Patent Application No. 18/428,570, titled “Combination Tr...
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name
Quoin Pharmaceuticals (QNRX) announced that the FDA has conditionally approved Qyleki as the proposed brand name for QRX003, the company’s investigational product candidate for the treatment of Nether...
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiat...
Quoin Pharmaceuticals completes establishment of subsidiary in Japan
Quoin Pharmaceuticals (QNRX) announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Nethe...
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va...
Quoin reports positive pediatric data in Netherton Syndrome program
Quoin Pharmaceuticals (QNRX) announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluating its drug candidate, QRX003. Four of the six enrolle...
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Ar...